Neurological Institute Outcomes
Anti-Calcitonin Gene Related Peptide Antibody Therapy for Migraine
Cleveland Clinic’s Section of Headache and Facial Pain, within the Center for Neurological Restoration, is among the largest and most comprehensive centers in the world dedicated to managing and treating headache and facial pain syndromes.
Outcomes Following Treatment with CGRP Monoclonal Antibodies (N=165)
CGRP = calcitonin gene-related peptide, HIT-6 = Headache Impact Test, PDI = Pain Disability Index, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System
Treatments targeting calcitonin gene-related peptide (CGRP) were approved by the FDA in 2018 and are an innovative treatment for patients with migraine. Cleveland Clinic’s Headache Section has prescribed these treatments for nearly 2000 patients. In 2018, 165 headache patients treated with CGRP therapy were reviewed; 90% had improved Headache Impact Test™ (HIT-6™) scores¹ and Pain Disability Index (PDI) scores.² All patients had improved or stable Patient-Reported Outcomes Measurement Information System (PROMIS) pain scores³ and 94% of patients had improved or stable depression scores on the Patient Health Questionnaire (PHQ-9).⁴